Your browser is no longer supported. Please, upgrade your browser.
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own0.10% Shs Outstand138.43M Perf Week-4.80%
Market Cap357.14M Forward P/E- EPS next Y-0.65 Insider Trans0.00% Shs Float137.92M Perf Month-12.84%
Income-80.30M PEG- EPS next Q-0.14 Inst Own86.10% Short Float4.12% Perf Quarter-28.13%
Sales- P/S- EPS this Y-37.60% Inst Trans-0.98% Short Ratio5.06 Perf Half Y-15.96%
Book/sh2.13 P/B1.21 EPS next Y-20.40% ROA-24.40% Target Price5.58 Perf Year-47.13%
Cash/sh2.07 P/C1.25 EPS next 5Y17.58% ROE-25.30% 52W Range2.33 - 5.19 Perf YTD-10.42%
Dividend- P/FCF- EPS past 5Y0.50% ROI- 52W High-50.77% Beta0.86
Dividend %- Quick Ratio35.90 Sales past 5Y- Gross Margin- 52W Low9.66% ATR0.15
Employees88 Current Ratio35.90 Sales Q/Q- Oper. Margin- RSI (14)40.20 Volatility5.47% 5.18%
OptionableYes Debt/Eq0.00 EPS Q/Q24.60% Profit Margin- Rel Volume0.36 Prev Close2.58
ShortableYes LT Debt/Eq0.00 EarningsAug 14 BMO Payout- Avg Volume1.12M Price2.56
Recom2.00 SMA20-3.18% SMA50-9.33% SMA200-20.96% Volume79,416 Change-0.97%
May-21-18Upgrade Barclays Underweight → Equal Weight $5
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-10-15Reiterated Maxim Group Buy $22 → $19
Aug-15-18 04:05PM  Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer GlobeNewswire
Aug-08-18 07:30PM  Achillion: 2Q Earnings Snapshot Associated Press
04:05PM  Achillion Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-11-18 11:05AM  Achillion's 3rd Factor D Inhibitor Enters Clinical Studies Zacks
Jul-10-18 06:05AM  Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D GlobeNewswire
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-22-18 08:18AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. Motley Fool
Jun-14-18 06:05AM  Achillion to Present at the 2018 JMP Securities Life Sciences Conference GlobeNewswire
Jun-01-18 10:40AM  Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound? Zacks
07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
May-31-18 08:32AM  Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert Zacks
May-21-18 01:56PM  SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion Benzinga
07:40AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
May-11-18 06:05AM  Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress GlobeNewswire
May-04-18 07:35AM  Wired News -Esperion Reported Positive Top-line Results from Late Stage Safety Study of its Cholestrol Drug - Bempedoic Acid ACCESSWIRE
06:35AM  Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
May-03-18 10:27AM  Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO Zacks
May-02-18 09:09AM  Achillion: 1Q Earnings Snapshot Associated Press
06:35AM  Achillion Reports First Quarter 2018 Financial Results and Management Transition GlobeNewswire
Apr-09-18 08:30AM  Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V Discovering Underlying Factors of Influence GlobeNewswire
Mar-20-18 08:37AM  Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-13-18 07:35AM  Report: Developing Opportunities within Mimecast, Mazor Robotics, JD, Achillion Pharmaceuticals, Kulicke and Soffa Industries, and Weibo Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-08-18 06:05AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire +7.80%
Mar-05-18 07:00AM  Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now Insider Monkey
Mar-01-18 12:16PM  [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna
Feb-28-18 06:05AM  Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G Initiative as Part of Rare Disease Day 2018 GlobeNewswire -5.52%
Feb-27-18 08:44AM  Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session Zacks
08:30AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Novavax ACCESSWIRE
07:40AM  Wired News Bellicum Pharma Shares Update On Clinical Hold of BPX-501 Studies in the US ACCESSWIRE
Feb-26-18 06:14PM  Why Achillion Pharmaceuticals, Inc. Stock Spiked Today Motley Fool +15.40%
08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
06:05AM  Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy GlobeNewswire
Feb-23-18 09:19AM  Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost Zacks
Feb-22-18 12:43PM  Was Achillion Pharmaceuticals Incs (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
06:21AM  Achillion reports 4Q loss Associated Press
06:05AM  Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-09-18 06:05AM  Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Dec-28-17 09:45AM  Actinium Posts Positive DMC View on Lomab-B Phase III Trial Zacks
Dec-27-17 11:29AM  Insys' Cannabidiol Gets Fast Track Designation in the U.S. Zacks
08:11AM  Alexion's (ALXN) Soliris Label Expansion Approved in Japan Zacks
Dec-26-17 09:17AM  BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA Zacks
Dec-20-17 12:12PM  CORRECTION - Achillion Pharmaceuticals, Inc. GlobeNewswire
06:05AM  Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D GlobeNewswire
Dec-18-17 06:30AM  Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study GlobeNewswire
Dec-13-17 03:46PM  Allergan Inks Deal to Buy Texas-Based Repros Therapeutics Zacks
Dec-12-17 05:58PM  Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma Zacks
Dec-06-17 02:10PM  Revance's Neuromodulator Injection Positive in Phase III Zacks
Dec-05-17 08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals ACCESSWIRE
Dec-04-17 09:03AM  Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug Zacks
Dec-01-17 05:51PM  Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 Zacks
Nov-27-17 12:48PM  [$$] J&J Lost $175 Million on Achillion Stock Investment
Nov-23-17 09:12AM  Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler Zacks
08:42AM  Puma Inks License Deal to Commercialize Cancer Drug Nerlynx Zacks
Nov-20-17 03:42PM  Agios Posts New Data on Glioma Candidate from Dose Expansion Zacks
Nov-16-17 03:36PM  Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today Motley Fool +17.49%
10:35AM  Achillion Pharmaceuticals Gears Up for Secondary Offering 24/7 Wall St.
08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia Pharmaceuticals ACCESSWIRE
Nov-15-17 10:05PM  Achillion Announces Pricing of Secondary Offering Of Common Stock GlobeNewswire -17.89%
01:37PM  Why Achillion Pharmaceuticals Stock Is Falling Today Motley Fool
01:30PM  Achillion (ACHN) Shares Down as J&J Announces Stake Sale Zacks
12:28PM  Achillion Heel: Stock Plunges as J&J Exits
08:16AM  Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer Zacks
06:36AM  Cardinal Health (CAH) to Divest Assets to Shanghai Pharma Zacks
Nov-14-17 04:53PM  Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin Zacks
04:34PM  Achillion shares drop as J&J to sell large stake MarketWatch
04:03PM  Achillion Announces Proposed Secondary Offering of Common Stock GlobeNewswire
04:01PM  Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G GlobeNewswire
09:48AM  Glaxo's Subcutaneous Formulation of Benlysta Approved in EU Zacks
Nov-06-17 06:05AM  Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Nov-03-17 01:08PM  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus Zacks
Nov-01-17 06:02PM  Achillion reports 3Q loss Associated Press
04:05PM  Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs GlobeNewswire
12:25PM  Has Achillion Pharmaceuticals Inc (ACHN) Got Enough Cash To Cover Its Short-Term Obligations? Simply Wall St.
Oct-24-17 06:05AM  USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor GlobeNewswire
Oct-23-17 07:00AM  Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting GlobeNewswire
Oct-18-17 10:08AM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : October 18, 2017 Capital Cube
Oct-17-17 08:15AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : October 17, 2017 Capital Cube
Sep-20-17 06:05AM  Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series GlobeNewswire +5.96%
Sep-15-17 06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
Sep-12-17 11:39AM  Achillion's HCV Partnership with J&J Terminated, Stock Falls Zacks
11:30AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : September 12, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Sep-11-17 04:30PM  Why Achillion Pharmaceuticals Crashed 22.2% Today Motley Fool -22.10%
09:46AM  Achillion Shares Are Plunging on Termination of Hepatitis C Pact
08:50AM  Achillion Pharma Slides After Hep C Deal Is Terminated 24/7 Wall St.
08:34AM  Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends CNBC
03:02AM  Achillion Announces Strengthening of Management Team GlobeNewswire
03:01AM  Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen GlobeNewswire
Aug-16-17 04:30PM  Edited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT Thomson Reuters StreetEvents
Aug-11-17 07:20AM  Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor ACCESSWIRE +5.98%
Aug-10-17 11:06AM  Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence -7.90%
08:21AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017 Capital Cube
08:20AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE
Aug-09-17 01:06PM  2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July Motley Fool +19.95%
12:57PM  Why Achillion Pharmaceuticals Is Shooting 25% Higher Today Motley Fool
11:59AM  These Two Biotech Stocks Are Going Berserk on Wednesday
11:15AM  3 Biotech Stocks Under the Microscope on Wednesday 8/9/17 ACCESSWIRE
10:51AM  Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update Zacks
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FISHERMAN JASON SDirectorJun 06Option Exercise1.0520,00021,00070,000Jun 08 04:15 PM
JOHNSON & JOHNSON10% OwnerNov 20Sale2.7518,367,34650,510,2020Nov 22 11:44 AM